• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.87% Nasdaq Up0.34%

    Halozyme Therapeutics, Inc. (HALO)

    -NasdaqGS
    9.33 Down 0.13(1.37%) 4:00PM EST
    |After Hours : 9.33 0.00 (0.00%) 4:47PM EST
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingSep 30, 2014Jun 30, 2014Mar 31, 2014Dec 31, 2013
    Total Revenue 14,606   18,385   11,966   12,498  
    Cost of Revenue5,141  5,924  5,520  3,540  
    Gross Profit 9,465   12,461   6,446   8,959  
    Operating Expenses
    Research Development19,904  18,649  21,415  20,926  
    Selling General and Administrative8,587  8,752  10,250  9,357  
    Non Recurring -   -   -   -  
    Others -   -   -   -  
    Total Operating Expenses -   -   -   -  
    Operating Income or Loss (19,026) (14,940) (25,219) (21,324)
    Income from Continuing Operations
    Total Other Income/Expenses Net122  118  47  64  
    Earnings Before Interest And Taxes(18,904)(14,822)(25,172)(21,259)
    Interest Expense1,376  1,451  1,376  727  
    Income Before Tax(20,280)(16,273)(26,548)(21,987)
    Income Tax Expense -   -   -   -  
    Minority Interest -   -   -   -  
    Net Income From Continuing Ops(20,280)(16,273)(26,548)(21,987)
    Non-recurring Events
    Discontinued Operations -   -   -   -  
    Extraordinary Items -   -   -   -  
    Effect Of Accounting Changes -   -   -   -  
    Other Items -   -   -   -  
    Net Income (20,280) (16,273) (26,548) (21,987)
    Preferred Stock And Other Adjustments -   -   -   -  
    Net Income Applicable To Common Shares (20,280) (16,273) (26,548) (21,987)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.